Kymera Therapeutics Inc’s recently made public that its Chief Financial Officer Jacobs Bruce N. unloaded Company’s shares for reported $3.96 million on Sep 17 ’25. In the deal valued at $50.00 per share,79,220 shares were sold. As a result of this transaction, Jacobs Bruce N. now holds 227,409 shares worth roughly $13.62 million.
Then, BRUCE N. JACOBS bought 79,220 shares, generating $3,864,352 in total proceeds.
Before that, Mainolfi Nello sold 30,000 shares. Kymera Therapeutics Inc shares valued at $1,470,000 were divested by the Chief Executive Officer at a price of $49.00 per share. As a result of the transaction, Mainolfi Nello now holds 660,482 shares, worth roughly $39.56 million.
H.C. Wainwright reiterated its Kymera Therapeutics Inc [KYMR] rating to a Buy in a research note published on September 18, 2025; the price target was $70. A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in mid September with a ‘”an Overweight”‘ rating. RBC Capital Mkts began covering KYMR with “an Outperform” recommendation on September 16, 2025.
Price Performance Review of KYMR
On Monday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock jump 4.68% to $59.89. Over the last five days, the stock has gained 4.07%. Kymera Therapeutics Inc shares have risen nearly 38.19% since the year began. Nevertheless, the stocks have risen 48.87% over the past one year.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on 2025-09-30, dropping by 79184.0 shares to a total of 8.09 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 8.16 million shares. There was a decline of -0.98%, which implies that there is a negative sentiment for the stock.
